PCN3 Quality-Adjusted Survival in Patients With Wild-Type (WT) KRASs Metastatic Colorectal Cancer (mCRC) Receiving First-Line Therapy With Panitumumab Plus FOLFOX Versus FOLFOX Alone
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.1198
https://www.valueinhealthjournal.com/article/S1098-3015(12)02911-7/fulltext
Title :
PCN3 Quality-Adjusted Survival in Patients With Wild-Type (WT) KRASs Metastatic Colorectal Cancer (mCRC) Receiving First-Line Therapy With Panitumumab Plus FOLFOX Versus FOLFOX Alone
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)02911-7&doi=10.1016/j.jval.2012.08.1198
First page :
A409
Section Title :
Cancer
Open access? :
No
Section Order :
698